|Bid||3.6300 x 1000|
|Ask||3.6200 x 1200|
|Day's Range||3.6300 - 3.8500|
|52 Week Range||1.6500 - 7.1500|
|Beta (5Y Monthly)||1.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Transaction Expected to Close in the 2021 Third QuarterTel Aviv, Israel, June 16, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), a developer of innovative technology that enables the functional selection of stem cells, announced today that it has filed a registration statement, including a joint proxy statement/prospectus (“Proxy Statement”), with the Securities and Exchange Commission (SEC) in connection with its proposed strategic merger with privately-held Quoin Pharmac
Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO), (OTCQX: HCANF), (Germany: A9KN) today announced its financial and operational results for three months ending March 31, 2021 ("Q1 2021"). The Company reported record revenues of $9.9 million for Q1 2021, a 123% increase compared to the previous year. This included the sale of over 5.2 million grams of cannabis products principally to dispensaries in Oregon and California, a 253% year over year increase. Organic revenuei growth was 62%, the highest organic growth recorded in the Company's history. The Company also reported a gross profit of $2.0 million, an increase from $(172.2k) for the three months ended March 31, 2020 ("Q1 2020"). The adjusted gross profit was $2.2 million (compared to $117.4k in Q1 2020). The reported gross margin in Q1 2021 was 19.7% in comparison with -3.9% in Q1 2020. Complete results are reported in the Company's consolidated financial statements for the three months ended March 31, 2021 (the "Consolidated Financial Statements") and associated management's discussion and analysis (the "Q1 2021 MD&A").
Cellect Biotechnology Ltd (NASDAQ: APOP) has announced data from the Phase 1/2 study in Israel evaluating ApoGraft technology for Graft versus Host Disease (GvHD), a severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). All eleven patients enrolled for the trial were transplanted using the ApoGraft product and were engrafted on time. The primary objective, safety, and tolerability of ApoGraft administered to patients with hemato-oncology disorders was met, and no procedure-related adverse events were reported during the study. ApoGraft functionally selects cells to improve the safety and efficacy of regenerative medicine and cell therapies. Last month, the company announced a reverse merger agreement with a privately held Quoin Pharmaceuticals. The new entity will be listed on NASDAQ under the symbol 'QNRX.' Price Action: APOP shares are down 6.69% at $2.37 on the last check Monday. See more from BenzingaClick here for options trades from BenzingaOvid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological ConditionsHumanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.